Evidence map›Paper›PMID 38152056›Full record

ReviewAnnals of clinical and translational neurology2024

Clinicopathological features of graft versus host disease-associated myositis.

Tomoyuki Kazuta, Ayuka Murakami, Seiya Noda, Satoko Hirano, Hiroshi Kito, Koyo Tsujikawa, Hirotaka Nakanishi, Seigo Kimura, Kentaro Sahashi, Haruki Koike and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Tomoyuki KazutaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ayuka MurakamiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Seiya NodaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Satoko HiranoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi KitoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koyo TsujikawaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hirotaka NakanishiDepartment of Neurology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Seigo KimuraNational Hospital Organization Suzuka National Hospital, Suzuka, Japan.
Kentaro SahashiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruki KoikeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-9453-9311
National Institute of Technology, Suzuka College · JPNagoya University · JPAsanogawa General Hospital · JPSaga University · JPYokkaichi Municipal Hospital · JP

Funding

Japan Society for the Promotion of Science JP20H00527Japan Society for the Promotion of Science JP23H00420
6 · The paper itself

Abstract

BACKGROUND AND

objectiveChronic graft versus host disease (GVHD)-associated myositis targeting skeletal muscle is a relatively rare but potentially debilitating complication following allogeneic hematopoietic stem cell transplantation (HSCT). We reviewed the clinicopathological features of GVHD-associated myositis among patients receiving allogeneic HSCT to elucidate the cellular pathogenesis.

methodsWe retrospectively reviewed clinical data and muscle biopsy results from 17 consecutive patients diagnosed with GVHD-associated myositis at our institution between 1995 and 2019. Immunostaining findings of GVHD-associated myositis were compared to those of patients with anti-tRNA-synthetase antibody-associated myopathy (ASM) (n = 13) and dermatomyositis (DM) (n = 12).

resultsThe majority of patients with GVHD-associated myositis showed subacute or chronic progression of mild to moderate limb weakness together with elevated serum creatine kinase. These patients also exhibited mild C-reactive protein elevation but were negative for myositis-related autoantibodies. Programmed death-1 (PD-1)-positive cells were observed in muscle interstitium adjacent to myofibers expressing human leukocyte antigen (HLA)-DR. The interstitium was also HLA-DR-positive, similar to biopsy samples from ASM patients but not DM patients. The proportions of HLA-DR-positive muscle fibers and PD-1-positive interstitial cells were significantly higher in GVHD and ASM samples than DM samples. The PD-1-positive cells were mostly CD-8-positive lymphocytes. DISCUSSION: GVHD-associated myositis is characterized by HLA-DR-positive myofibers and infiltration of PD-1-positive lymphocytes. These features distinguish GVHD-associated myositis from DM but not from ASM.

Indexed as

Graft vs Host DiseaseMyositisHLA-DR AntigensHumansProgrammed Cell Death 1 ReceptorRetrospective StudiesHLA-DR AntigensProgrammed Cell Death 1 Receptor

Identifiers

PMID38152056
PMCPMC10863911
OpenAlexW4390343446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.